Bluejay Diagnostics, Inc.

NasdaqCM BJDX

Bluejay Diagnostics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 2,622,208

Bluejay Diagnostics, Inc. Shares (Diluted, Weighted) is 2,622,208 for the Trailing 12 Months (TTM) ending September 30, 2024, a 1,919.45% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Bluejay Diagnostics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 129,847, a 3.16% change year over year.
Bluejay Diagnostics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 125,872, a 30.79% change year over year.
Bluejay Diagnostics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 96,237.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqCM: BJDX

Bluejay Diagnostics, Inc.

CEO	Mr. Indranil Dey
IPO Date	Nov. 10, 2021
Location	United States
Headquarters	360 Massachusetts Avenue
Employees	10
Sector	Health Care
Industries Biotechnology Medical Instruments

Description

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Key trends

Past 5 years